David L. Lacey, MD
Dr. Lacey received both his undergraduate and medical degrees from the University of Colorado and he was elected to Phi Beta Kappa and Alpha Omega Alpha, respectively. To pursue his research interest in bone biology in conjunction with completing his post graduate medical education, he continued his training at Washington University, St. Louis, Missouri.
He transitioned from academia to industry when he joined Amgen. During the last five years of his tenure he assumed the head of Discovery Research (> 1200 FTEs) for Amgen. At any given time there were over 100 actively managed preclinical projects across four therapeutic areas: hematology/oncology, inflammation, metabolic disorders, and neuroscience. Amgen’s pipeline excellence was recognized externally by Scrip (November 2009) and R&D Directions (January 2011).
Scientifically, he played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen which led to the development of the anti-RANKL human mAb denosumab, an emerging dual blockbuster for both osteoporosis and cancer-related bone diseases. Denosumab received a number of awards including the US 2011 Prix Galien award for best new biotechnology product and the 2010 Scrip award for best new drug.
Following his career at Amgen, he continues to be active in the biopharmaceutical industry by advising academic institutions, biotechnology companies, and venture capital firms.